lenalidomide,carfilzomib,dexamethasone
amgen
#imw2022 data from the forte trial show that a level of circulating plasma cells (ctcs) higher than 0.07% is associated with poorer prognosis &gt; should we skip bmbx as long as patients have ctcs 
Director of the Multiple Myeloma and Amyloidosis Service @columbiacancer - Associate Editor @JCO_ASCO - Tweets are my own